[go: up one dir, main page]

HRP20220979T8 - Sastavi za liječenje amiloidoze - Google Patents

Sastavi za liječenje amiloidoze Download PDF

Info

Publication number
HRP20220979T8
HRP20220979T8 HRP20220979TT HRP20220979T HRP20220979T8 HR P20220979 T8 HRP20220979 T8 HR P20220979T8 HR P20220979T T HRP20220979T T HR P20220979TT HR P20220979 T HRP20220979 T HR P20220979T HR P20220979 T8 HRP20220979 T8 HR P20220979T8
Authority
HR
Croatia
Prior art keywords
compositions
treating amyloidosis
amyloidosis
treating
Prior art date
Application number
HRP20220979TT
Other languages
English (en)
Inventor
Gene G. Kinney
Spencer D. GUTHRIE
Martin Koller
Original Assignee
Prothena Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Limited filed Critical Prothena Biosciences Limited
Publication of HRP20220979T1 publication Critical patent/HRP20220979T1/hr
Publication of HRP20220979T8 publication Critical patent/HRP20220979T8/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20220979TT 2016-06-30 2017-06-30 Sastavi za liječenje amiloidoze HRP20220979T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30
EP17740200.5A EP3478713B1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis
PCT/US2017/040289 WO2018005967A1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis

Publications (2)

Publication Number Publication Date
HRP20220979T1 HRP20220979T1 (hr) 2022-11-11
HRP20220979T8 true HRP20220979T8 (hr) 2023-02-03

Family

ID=59351103

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220979TT HRP20220979T8 (hr) 2016-06-30 2017-06-30 Sastavi za liječenje amiloidoze

Country Status (16)

Country Link
US (2) US20190169280A1 (hr)
EP (1) EP3478713B1 (hr)
JP (3) JP2019519584A (hr)
CY (1) CY1125536T1 (hr)
DK (1) DK3478713T3 (hr)
ES (1) ES2914781T3 (hr)
HR (1) HRP20220979T8 (hr)
HU (1) HUE059400T2 (hr)
LT (1) LT3478713T (hr)
MA (1) MA45552A (hr)
PL (1) PL3478713T3 (hr)
PT (1) PT3478713T (hr)
RS (1) RS63446B1 (hr)
SI (1) SI3478713T1 (hr)
SM (1) SMT202200261T1 (hr)
WO (1) WO2018005967A1 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095100A1 (en) * 2018-03-23 2019-09-26 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
CA3129890A1 (en) * 2019-02-12 2020-08-20 Prothena Biosciences Limited Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
AU2020231081A1 (en) 2019-03-05 2021-09-30 Prothena Biosciences Limited Methods of treating AL amyloidosis
WO2021041884A1 (en) * 2019-08-30 2021-03-04 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
TW202216768A (zh) * 2020-06-22 2022-05-01 美商恩格姆生物製藥公司 Lair-1結合劑及其使用方法
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
HUE025560T2 (en) 2007-12-28 2016-03-29 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
JP6431372B2 (ja) * 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド 抗体製剤および方法

Also Published As

Publication number Publication date
PT3478713T (pt) 2022-05-27
EP3478713B1 (en) 2022-05-11
HUE059400T2 (hu) 2022-11-28
CY1125536T1 (el) 2025-05-09
US20190169280A1 (en) 2019-06-06
JP2024127990A (ja) 2024-09-20
DK3478713T3 (da) 2022-06-20
JP2019519584A (ja) 2019-07-11
LT3478713T (lt) 2022-06-10
HRP20220979T1 (hr) 2022-11-11
MA45552A (fr) 2019-05-08
RS63446B1 (sr) 2022-08-31
SI3478713T1 (sl) 2022-06-30
WO2018005967A1 (en) 2018-01-04
PL3478713T3 (pl) 2022-10-10
EP3478713A1 (en) 2019-05-08
ES2914781T3 (es) 2022-06-16
SMT202200261T1 (it) 2022-07-21
JP2022121658A (ja) 2022-08-19
US20210079078A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
IL261792B (en) Preparations
GB201715639D0 (en) Compositions for wound treatment
IL260933A (en) Preparations containing tocorsol or its analogues
GB201610156D0 (en) Cliptac compositions
LT3377516T (lt) Kompozicija vėžiui gydyti
PT3478713T (pt) Composições para tratamento da amiloidose
GB201600075D0 (en) Immunogenci composition
IL265255A (en) Dementia treatment preparations
GB201614799D0 (en) Compositions
GB201622161D0 (en) Compositions
GB201610628D0 (en) New compositions
GB201602658D0 (en) Compositions
GB201602579D0 (en) New compositions
SMT202300229T1 (it) Composizioni per trattare condizioni oftalmiche
IL246919A0 (en) New preparations for the treatment of mechanical nerve injuries
HK40008815A (en) Compositions for treating amyloidosis
IL268715A (en) Preparations for the treatment of acne
GB201510658D0 (en) Compositions for wound treatment
GB201614230D0 (en) Compositions
GB201611960D0 (en) Compositions
GB201611851D0 (en) Compositions
GB201602656D0 (en) Compositions
GB201604900D0 (en) Composition
GB201604899D0 (en) Composition
GB201604341D0 (en) Composition